Abstract
Objectives: A new national clinical guideline for the management of tuberculosis and HIV in Iranian prisons was released in 2011. The aim of this study was to compare HIV indicators in the case and control prisons after implementation of the new guideline.
Methods: This report examines outcomes observed during the pilot phase of its implementation at a case prison from October 2013 to June 2014 compared to a control prison that had not yet implemented the guideline. The case prison included incarcerated individuals in the Great Tehran Prison. A prison in Alborz province was considered as a control group. Pearson’s Chi-squared, two-sample t-test, paired t-test and Kruskal-Wallis were used for the analysis.
Results: The intervention significantly increased the total number of inmates tested for HIV and of diagnoses of HIV-positive inmates in the case prison compared to the control prison (P<0.001). Moreover, coverage of antiretroviral therapy was higher in the case prison compared to the control prison (P=0.015).
Conclusion: We recommend the implementation of this guideline in all Iranian prisons.
Keywords: HIV/AIDS, prison, guideline, indicators, HIV testing, antiretroviral therapy.
Infectious Disorders - Drug Targets
Title:Comparison of HIV Indicators after the Implementation of a New Model for TB and HIV Management in an Iranian Prison
Volume: 20 Issue: 6
Author(s): Behnam Farhoudi, SeyedAhmad SeyedAlinaghi*, Bahar Ataeinia, Mostafa Hosseini, Sirous Jafari, Ramin Alasvand, Mehrzad Tashakoriyan and Minoo Mohraz
Affiliation:
- Iranian Research Center for HIV/AIDS, Tehran University of Medical Sciences, Tehran,Iran
Keywords: HIV/AIDS, prison, guideline, indicators, HIV testing, antiretroviral therapy.
Abstract:
Objectives: A new national clinical guideline for the management of tuberculosis and HIV in Iranian prisons was released in 2011. The aim of this study was to compare HIV indicators in the case and control prisons after implementation of the new guideline.
Methods: This report examines outcomes observed during the pilot phase of its implementation at a case prison from October 2013 to June 2014 compared to a control prison that had not yet implemented the guideline. The case prison included incarcerated individuals in the Great Tehran Prison. A prison in Alborz province was considered as a control group. Pearson’s Chi-squared, two-sample t-test, paired t-test and Kruskal-Wallis were used for the analysis.
Results: The intervention significantly increased the total number of inmates tested for HIV and of diagnoses of HIV-positive inmates in the case prison compared to the control prison (P<0.001). Moreover, coverage of antiretroviral therapy was higher in the case prison compared to the control prison (P=0.015).
Conclusion: We recommend the implementation of this guideline in all Iranian prisons.
Export Options
About this article
Cite this article as:
Farhoudi Behnam, SeyedAlinaghi SeyedAhmad*, Ataeinia Bahar, Hosseini Mostafa, Jafari Sirous, Alasvand Ramin, Tashakoriyan Mehrzad and Mohraz Minoo, Comparison of HIV Indicators after the Implementation of a New Model for TB and HIV Management in an Iranian Prison, Infectious Disorders - Drug Targets 2020; 20 (6) . https://dx.doi.org/10.2174/1871526519666191015151639
DOI https://dx.doi.org/10.2174/1871526519666191015151639 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Discovery of Anticancer Agents from 2-Pyrazoline-Based Compounds
Current Medicinal Chemistry Role of Defensins and Cathelicidin LL37 in Auto-Immune and Auto- Inflammatory Diseases
Current Pharmaceutical Biotechnology Nicotinamide Supplementation Protects Gestational Diabetic Rats by Reducing Oxidative Stress and Enhancing Immune Responses
Current Medicinal Chemistry Evaluation of the QuantiFERON®-TB Gold In-Tube Assay and Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in an Iranian Referral Hospital
Infectious Disorders - Drug Targets Computational Approaches for Fragment-Based and De Novo Design
Current Topics in Medicinal Chemistry Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism Isoniazid Resistance and Dosage as Treatment for Patients with Tuberculosis
Current Drug Metabolism Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology
Current Medicinal Chemistry The Antibiotic Potential of Prokaryotic IMP Dehydrogenase Inhibitors
Current Medicinal Chemistry Tackling Drug-Resistant Tuberculosis: Current Trends and Approaches
Mini-Reviews in Medicinal Chemistry Targeting the Peptide Deformylase of Mycobacterium tuberculosis Leads to Drug Discovery
Letters in Drug Design & Discovery Chemistry and Applications of 4-Hydroxyquinolin-2-one and Quinoline-2,4-dionebased Compounds
Current Organic Chemistry Synthesis of 99mTc-Rifabutin: A Potential Tuberculosis Radiodiagnostic Agent
Infectious Disorders - Drug Targets Current Trends and Future Directions of Fluoroquinolones
Current Medicinal Chemistry Development of Aminoglycoside Antibiotics by Carbohydrate Chemistry
Mini-Reviews in Medicinal Chemistry Thiazoles and Thiazolidinones as Antioxidants
Current Medicinal Chemistry Efficient Transfection of Phosphorothioate Oligodeoxyribonucleotides by lipofectamine2000 into Different Bacteria
Current Drug Delivery Anti-Tuberculosis
Current Bioactive Compounds Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) AMP-activated Protein Kinase As a Target For Pathogens: Friends Or Foes?
Current Drug Targets